Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Recurrent Endometrial Cancer”

129 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 129 results

Large-scale testing (Phase 3)Study completedNCT01767155
What this trial is testing

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Who this might be right for
Endometrial Cancer
AEterna Zentaris 511
Early research (Phase 1)Looking for participantsNCT05691504
What this trial is testing

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Who this might be right for
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube Carcinoma+8 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT06317311
What this trial is testing

Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Who this might be right for
Carcinoma
GlaxoSmithKline 41
Testing effectiveness (Phase 2)Study completedNCT00607607
What this trial is testing

Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
CASI Pharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Study completedNCT00502203
What this trial is testing

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Who this might be right for
Mixed Tumor, Mullerian
M.D. Anderson Cancer Center 23
Early research (Phase 1)Study completedNCT00005842
What this trial is testing

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Cancer
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Study completedNCT00006357
What this trial is testing

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Who this might be right for
Endometrial CancerGastrointestinal Stromal TumorOvarian Cancer+2 more
European Organisation for Research and Treatment of Cancer - EORTC 91
Testing effectiveness (Phase 2)Study completedNCT00006377
What this trial is testing

Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01013324
What this trial is testing

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

Who this might be right for
Endometrial CancerEndometrial Neoplasms
Sanofi 67
Large-scale testing (Phase 3)Ended earlyNCT00883116
What this trial is testing

Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Who this might be right for
Endometrial Cancer
R-Pharm 551
Early research (Phase 1)Study completedNCT00659568
What this trial is testing

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Who this might be right for
Breast CancerEndometrial CancerKidney Cancer+3 more
London Health Sciences Centre 28
Testing effectiveness (Phase 2)Study completedNCT02632448
What this trial is testing

LY2880070 in Participants With Advanced or Metastatic Cancer

Who this might be right for
Solid TumorsColorectal CancerBreast Cancer+9 more
Esperas Pharma Inc. 229
Not applicableLooking for participantsNCT06890273
What this trial is testing

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Who this might be right for
Endometrial Cancer
AstraZeneca 150
Testing effectiveness (Phase 2)Study completedNCT02730429
What this trial is testing

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Who this might be right for
Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit 78
Early research (Phase 1)Study completedNCT00082823
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Testing effectiveness (Phase 2)WithdrawnNCT03005015
What this trial is testing

Lenvatinib in Second Line Endometrial Carcinoma

Who this might be right for
Endometrial Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC
Not applicableStudy completedNCT01164735
What this trial is testing

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Recurrent Uterine Corpus CarcinomaStage III Uterine Corpus CancerStage IV Uterine Corpus Cancer
Gynecologic Oncology Group 169
Testing effectiveness (Phase 2)UnknownNCT01461759
What this trial is testing

Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer

Who this might be right for
Advanced or Recurrent Endometrial Cancer
Asan Medical Center 59
Early research (Phase 1)Study completedNCT00066404
What this trial is testing

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Who this might be right for
Cancer
Abramson Cancer Center at Penn Medicine
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Load More Results